Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Binding bids: Fortis...

    Binding bids: Fortis Healthcare board to meet again today

    Written by Ruby Khatun Khatun Published On 2018-04-27T10:32:02+05:30  |  Updated On 27 April 2018 10:32 AM IST
    Binding bids: Fortis Healthcare board to meet again today

    New Delhi: A meeting of Fortis Healthcare board yesterday remained inconclusive on the binding bids by the likes of Malaysian firm IHH Healthcare, Manipal/TPG consortium, Munjal and Burman family offices and KKR-backed Radiant Life Care, and will again be held today.


    The board met for five hours yesterday but was handicapped by the resignation of Renuka Ramnath from the expert panel formed to evaluate the binding bids and make final recommendations to the board, Fortis Healthcare said in regulatory filing.


    Ramnath, former MD, and CEO of ICICI Venture resigned from the expert committee on April 25, it added.


    "Owing to the resignation caused by Renuka Ramnath, one of the esteemed members of the expert advisory committee constituted by the Board of Directors of Fortis Healthcare, the binding bids for the proposed transaction of fundraising and/or re-structuring the company, could not be deliberated upon, at its meeting held yesterday (April 25)," FHL said.


    Accordingly, the board at its meeting held today decided to adjourn the meeting to be re-convened to April 27, 2018, it added.


    The company's board also extended an invitation to Suvalaxmi Chakraborty, Ravi Rajagopal, and Indrajit Banerjee to join immediately as additional independent directors and accordingly attend the meeting, subject to their acceptance towards the same, Fortis Healthcare said.


    Their names have been recommended by National Westminster Bank Plc as Trustee of Jupiter India Fund, East Bridge Capital Master Fund Ltd and East Bridge Capital Master Fund I Ltd, which have an aggregate of 12.04 percent of the paid-up capital of the company.


    "It was also decided that in the meeting scheduled for tomorrow and in light of the above new appointments, the board shall discuss further board restructuring," FHL said.


    Already, four entities -- KKR-backed Radiant Life Care, Malaysian major IHH Healthcare, Manipal/TPG consortium and Munjal and Burman family offices -- have given binding offers to the board of FHL.


    While Manipal Health Enterprises again revised its offer for Fortis Healthcare on April 25, raising the value of the hospitals business to Rs 6,322 crore.


    KKR-backed Radiant Life Care has also made a revised bid for Fortis Healthcare Ltd (FHL) with a binding offer to acquire its Mulund hospital for an enterprise value of Rs 1,200 crore.


    Malaysian major IHH Healthcare has also revised its proposal and made a binding offer to immediately infuse Rs 650 crore in the Indian firm as part of an overall proposal to invest Rs 4,000 crore.


    Besides, FHL has received a binding offer from Hero Enterprise Investment Office and Burman Family Office. Group entities of Hero Enterprise Investment Office led by Sunil Kant Munjal and the Burman family of the Dabur Group currently hold around 3 percent stake in the healthcare chain.


    FHL had also received an unsolicited non-binding expression of interest from Fosun Health Holdings, an arm of Fosun International, with a proposal of primary infusion at a price up to Rs 156 per share up to a total investment of USD 350 million (over Rs 2,295 crore).

    Binding bidsboardBurman Family OfficeDabur GroupFHLFortisFortis HealthcareHero Enterprise Investment OfficeICICI ventureIHH HealthcareinvitationManipalRenuka RamnathresignationTPG
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok